Teen Scientist Creates Novel Diagnostic Tool for Inflammatory Bowel Disease (IBD)

From May 16 to May 21, 2021, nearly 2,000 young scientists, engineers, entrepreneurs and inventors convened virtually for a week of connecting with their peers and global STEM leaders, events, and $5 million in awards and prizes. The finalists, selected from nearly 400 affiliate fairs in 64 countries, regions and territories, have all completed exemplary... Read more

PerkinElmer Provides Update on Second Quarter Performance and Schedules Earnings Call for Wednesday, July 28, 2021

Company anticipates 2Q21 revenue and earnings to be above previously communicated guidance WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 24, 2021– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced ahead of this morning’s Virtual Investor and Analyst Day that it anticipates exceeding its previously announced financial guidance for the second quarter... Read more

PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech

Solutions to complement Company’s growing position in cell and gene therapy research and development WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 22, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) is pleased to announce it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector-based technologies that drive improved delivery performance for cell and gene... Read more

Bruker Updates FY 2021 Guidance and Provides Medium Term Outlook at Virtual Investor Day

BILLERICA, Mass.–(BUSINESS WIRE)– At its 2021 Virtual Investor Day today, Bruker Corporation (Nasdaq: BRKR) will discuss the Company’s strategy and Project Accelerate 2.0 initiatives, including the Company’s potential high-growth opportunities in the areas of proteomics and spatial biology. Bruker will also update its fiscal year 2021 guidance and will discuss its medium term financial outlook... Read more

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia

Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years after completion of a one-year fixed-duration treatment with Venclexta/Venclyxto plus Gazyva/Gazyvaro1 New phase III MURANO study data suggested certain genetic risk factors may help tailor treatments for patients with... Read more

World Ocean Day – One Ocean, One Climate, One Future

June 8, 2021 marks World Ocean Day. About 71 percent of the Earth’s surface is (salt) water-covered, and the oceans hold about 96.5 percent of all Earth’s water. Time to appreciate the unique value of our oceans. Ocean currents govern the world’s weather and create a kaleidoscope of life. Humans depend on these crowded waters... Read more

Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma

Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June 2021 ‒ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b... Read more

Nanoflowers as Next Generation Catalysts

Nanoflowers are nanostructures which, when viewed with scanning electron microscopy, resemble flowers or trees. They are of interest to scientists because of their high stability and enhanced efficiency. Their applications range from optoelectronics devices or sensors, catalysis and solar cells as well as uses in nanotechnology. Associate Professor İsmail Öçsoy is a teacher and researcher... Read more

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy

With hypomethylating agents significantly improved complete response rates in certain adults with newly diagnosed acute myeloid leukaemia In the VIALE-A study, Venclyxto plus azacitidine significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall survival rate of less than 10%1 Study data reinforces the potential of... Read more

Consolidated Financial Statements for the Year Ended March 31, 2021 FY2021 (April 1, 2020 – March 31, 2021) [UNAUDITED]

This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more